T1000	Speculation 2051 2065	indicated that
E1000	Speculation:T1000 Scope:T1001
T1001	Span 2051 2278	indicated that total FoxO1 levels were greatly decreased in wild-type and LMP1 transgenic lymphomas (Figure 6B), suggesting that inhibition of the Forkhead signaling pathway is an important target of Akt in lymphoma development
T1002	Negation 1869 1872	not
E1001	Negation:T1002 Scope:T1003
T1003	Span 1869 1907	not consistently detect p-FoxO1 levels
T1004	Negation 2325 2328	not
E1002	Negation:T1004 Scope:T1005
T1005	Span 2325 2380	not induce FoxO1 degradation in LMP1 transgenic B cells
T1006	Speculation 2164 2174	suggesting
E1003	Speculation:T1006 Scope:T1007
T1007	Span 2164 2278	suggesting that inhibition of the Forkhead signaling pathway is an important target of Akt in lymphoma development
T1008	Speculation 2386 2389	may
E1004	Speculation:T1008 Scope:T1009
T1009	Span 2386 2424	may not be the sole regulator of FoxO1
T1010	Negation 2390 2393	not
E1005	Negation:T1010 Scope:T1011
T1011	Span 2390 2424	not be the sole regulator of FoxO1
T1012	Speculation 2818 2825	whether
E1006	Speculation:T1012 Scope:T1013
T1013	Span 2818 2895	whether LMP1 affected cell cycle regulation through the Rb pathway in B cells
T1014	Speculation 2433 2436	may
E1007	Speculation:T1014 Scope:T1015
T1015	Span 2433 2509	may be that progression to lymphoma requires modulation of multiple pathways
T1016	Speculation 3351 3364	indicate that
E1008	Speculation:T1016 Scope:T1017
T1017	Span 3351 3502	indicate that the Rb pathway is deregulated in LMP1 transgenic lymphocytes and that lymphoma cells are distinguished by loss of FoxO1 and decreased p27
T1018	Negation 626 629	not
E1009	Negation:T1018 Scope:T1019
T1019	Span 626 658	not further increase pAkt levels
T1020	Speculation 291 293	if
E1010	Speculation:T1020 Scope:T1021
T1021	Span 291 344	if Akt signaling is activated in LMP1 transgenic mice
T1022	Negation 925 928	not
E1011	Negation:T1022 Scope:T1023
T1023	Span 925 1008	not a target of activated Akt in the LMP1 transgenic lymphocytes and lymphoma cells
T1024	Negation 787 790	not
E1012	Negation:T1024 Scope:T1025
T1025	Span 763 829	phosphorylated GSK3 was not detected in the transgenic lymphocytes
T1026	Negation 1039 1046	without
E1013	Negation:T1026 Scope:T1027
T1027	Span 1039 1070	without phosphorylation of GSK3
T1028	Speculation 902 916	indicates that
E1014	Speculation:T1028 Scope:T1029
T1029	Span 902 1008	indicates that GSK3 is not a target of activated Akt in the LMP1 transgenic lymphocytes and lymphoma cells
T1030	Negation 1423 1426	not
E1015	Negation:T1030 Scope:T1031
T1031	Span 1402 1485	Activated p-mTOR was not increased in LMP1 transgenic lymphocytes or lymphoma cells
T1032	Speculation 1240 1248	suggests
E1016	Speculation:T1032 Scope:T1033
T1033	Span 1240 1312	suggests that additional pathways are involved in the regulation of GSK3
T1034	Speculation 1487 1502	indicating that
E1017	Speculation:T1034 Scope:T1035
T1035	Span 1487 1562	indicating that this pathway is not affected by LMP1-induced Akt activation
T1036	Negation 1519 1522	not
E1018	Negation:T1036 Scope:T1037
T1037	Span 1503 1622	this pathway is not affected by LMP1-induced Akt activation and does not contribute to lymphoma development (Figure 6B)
